Strickland, M., Lee, E. Q., Wang, N., Cohen, J., Chukwueke, U., Forst, D., Eichler, A., Overmoyer, B., Lin, N., Chen, W., Bardia, A., Juric, D., Dagogo-Jack, I., White, M., Dietrich, J., Nayyar, N., Kim, A., Alvarez-Breckenridge, C., Mahar, M., Mora, J., Nahed, B., Jones, P., Shih, H., Gerstner, E., Giobbie-Hurder, A., Carter, S., Oh, K., Cahill, D., Sullivan, R., & Brastianos, P. (2021). cTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. Neuro-oncology, 23, vi49. http://access.bl.uk/ark:/81055/vdc_100146090606.0x000030